FDA approves J&J’s BCMA-targeted bispecific for multiple myeloma

The FDA on Tuesday approved Johnson & Johnson’s Tecvayli (teclistamab), a BCMA-directed bispecific antibody, looking to head into an already crowded field of treatments aiming to help those with the blood cancer multiple myeloma.

The accelerated approval follows promising early efficacy in 40 patients, with 65% of patients having a...

Click to view original post